veltuzumab   Click here for help

GtoPdb Ligand ID: 8268

Synonyms: hA20 | IMMU-106
Immunopharmacology Ligand
Compound class: Antibody
Comment: Veltuzumab is a humanized monoclonal antibody targeting CD20. With the exeption of Asp101 in the complementarity-determining region 3 (CDR3) of the antibody's variable heavy chain, its CDRs are identical to rituximab [2]. This single amino acid substitution appears to account for veltuzumab's reduced off-rate compared to rituximab [2] as well as its enhanced capacity to induce antibody-dependent cellular cytotoxicity (ADCC), and complement-mediated cytotoxicity.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB link.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
The EMA and FDA have granted veltuzumab orphan designation for the treatment of the rare disease chronic lymphocytic leukemia (CLL). The FDA also includes treatment of pemphigus (a group of autoimmune diseases causing severe blistering of the skin and mucous membranes) in its orphan drug designation. Phase 2 clinical trials for non-Hodgkin's lymphoma, CLL and autoimmune thrombocytopenic purpura are ongoing.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
CD20 appears to function as a regulator of B cell maturation, facilitating an effective B-cell immune response [1,3]. CD20-specific monoclonal antibodies are commonly used for the treatment of B cell malignancies and autoantibody-mediated autoimmune diseases, although the precise mechanism of action is not fully understood.